Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Purple Biotech Q3 EPS $(0.27)

Purple Biotech Q3 EPS $(0.27)

Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.27) per share.

byBill Haddad

November 8, 2022

1 minute read

Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.27) per share.

Barclays Maintains Overweight on Helmerich & Payne, Raises Price Target to $58

By Benzinga Newsdesk

August 1, 7:10 AM

Barclays analyst David Anderson maintains Helmerich & Payne (NYSE:HP) with a Overweight and raises the price target from $52 to $58.

Why Steelcase Stock Tanked After-Hours

By Ryan Gustafson

December 19, 6:16 PM

Steelcase Inc. (NYSE: SCS) shares are trading lower in Tuesday's after-hours session after the company reported mixed third-quarter financial results.

SCS

California’s Underground Marijuana Market Flourishes: Which Companies Remain Resilient Amid Illicit Competition?

By Nicolas Jose Rodriguez

April 9, 9:19 AM

Sales Decline And Market Dynamics Recent market updates suggest a decline in California's cannabis sector despite a consistent number of licensed storefronts.

GHBWF

Innovation Passport Granted For CRN04777 For The Treatment Of Congenital Hyperinsulinism

By Benzinga Newsdesk

October 6, 8:13 AM

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted CRN04777 an "Innovation Passport" for the

CRNX

Purple Biotech Q3 EPS $(0.27)

Related Posts

Barclays Maintains Overweight on Helmerich & Payne, Raises Price Target to $58

Why Steelcase Stock Tanked After-Hours

California’s Underground Marijuana Market Flourishes: Which Companies Remain Resilient Amid Illicit Competition?

Innovation Passport Granted For CRN04777 For The Treatment Of Congenital Hyperinsulinism